Recent briefings covering the period surrounding this report noted broad equity market movement, with the Nasdaq 100 adding approximately $3.5 trillion in market capitalisation over four consecutive trading sessions through mid-August 2026, attributed to strong corporate earnings and renewed interest in technology sectors [Brief - 2026-09-19] [Brief - 2026-09-11]. These broader market conditions formed the backdrop against which CVS Health Corp. activity was observed during the quarter.
CVS Health Corp. reported trailing twelve-month revenue of approximately $415.1 billion as of 30 June 2026, representing year-over-year growth of 7.26%. Net income for the same period stood at approximately $4.9 billion, with a net margin of 1.18% and an operating margin of 1.997%. Gross margin was recorded at 7.06%. Earnings per share grew 188.75% year-over-year. The company held $11.33 billion in cash against total debt of $63.48 billion, with a price-to-earnings ratio of 23.52 and a market capitalisation of approximately $113.9 billion [SEC 10-Q - CVS - 2026-06-30].
This report was triggered by material institutional position changes. Four prominent asset managers each opened new positions in CVS during the most recent reporting period: Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio) all initiated holdings [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data was available for inclusion in this report.
The prevailing macroeconomic environment reflected a normal yield curve, with the 10-year US Treasury yield at 5.18% and the 2-year yield at 4.87% [FRED DGS10] [FRED DGS2]. The spread of 31 basis points between the two tenors indicates a modestly upward-sloping curve, a condition that has implications for cost-of-debt dynamics for highly leveraged issuers across the healthcare and pharmacy benefit management sectors.